Budapest Post

Cum Deo pro Patria et Libertate
Budapest, Europe and world news

FDA Approves New HIV-Prevention Drug, but Not for Women

FDA Approves New HIV-Prevention Drug, but Not for Women

The Food and Drug Administration on Thursday approved a new drug, Descovy, for prevention of infection with HIV, only the second drug approved for this purpose.The first, Truvada, has become a mainstay of government efforts to turn back the HIV epidemic. But the FDA approved Descovy for use only in men
The Food and Drug Administration on Thursday approved a new drug, Descovy, for prevention of infection with HIV, only the second drug approved for this purpose.

The first, Truvada, has become a mainstay of government efforts to turn back the HIV epidemic. But the FDA approved Descovy for use only in men and transgender women, because its maker, Gilead Sciences, tested it only in those groups.

The approval explicitly excludes women and does not outline a plan for making the drug available to them. Some activists and scientists said the approval sets a dangerous precedent by allowing companies to dodge expensive trials needed to test medicines in women.

Such an exclusion of women “should be unacceptable in these days and times,” said Dr. Rochelle Walensky, chief of infectious diseases at Massachusetts General Hospital.

It’s important to test the drug specifically in women, she added, because Descovy may work differently in the vagina than in rectal tissues.

The FDA, in fact, will require Gilead to study Descovy in women, company officials said. Gilead is considering a trial in Africa.

Gilead also makes Truvada. Both medicines are to be taken daily, an HIV-prevention strategy called preexposure prophylaxis, or PrEP.

The company has come under heavy criticism for selling Truvada at a high cost, currently about $20,000 a year. Critics have said the expense keeps the drug out of reach of Americans who would benefit from it. Few patients actually pay the full price, Gilead has said.

Less expensive generic versions of Truvada are expected next year, as the drug’s patent protections expire. But Descovy’s approval ensures Gilead’s continued dominance of the market for PrEP, said Jeremiah Johnson, a project director at Treatment Action Group, an advocacy organization.

Descovy is not more effective than Truvada, Johnson noted. But in various presentation materials, Gilead on occasion has hinted that it is, and Johnson and others fear patients may reject affordable and accessible generic versions of Truvada in favor of the more expensive Descovy.

Any suggestion that Descovy is more effective than Truvada was unintentional, said Diana Brainard, who oversees Gilead’s HIV division. The company’s message, she added, is that both Descovy and Truvada are highly effective at preventing HIV infection when taken daily.

“It’s always good to have choice,” she said.

Descovy’s patent is supposed to expire in 2026, but a nonprofit group called Prep4All Collaboration hopes to find a way to end it in 2022.

The group had been running a campaign called “Break the Patent” to limit Truvada’s patent protection, which was supposed to expire in 2021. But in May, Gilead announced that a generic version would be available next year.

“As of today, we’re adding an ‘s’ — it’s ‘Break the Patents,’ ” said Peter Staley, a founder of the collaboration.

Descovy contains a newer version of tenofovir, the active ingredient in Truvada. Gilead tested Descovy in a multinational trial that included 5,313 men and 74 transgender women who have sex with men. There were no cisgender women, and 84% of the participants were white.

“They did a terrible job of inclusion for a company that dominates the market,” Johnson said.

There are some data suggesting that Descovy has fewer side effects on bones and kidneys than Truvada, but those problems have only been seen in a small number of people taking Truvada, Walensky said.

She also noted that although Gilead scientists have presented some of their data at conferences, they have yet to publish their results in a peer-reviewed journal.

At a hearing in August, some activists urged the FDA to deny approval for use of Descovy in women or to require Gilead to test the drug in a large number of women promptly after approval.

Unless forced to do so by the FDA, critics said, the company has no motivation to test the drug in women.

“We had at least hoped that they would say something the day they approved it without an indication for women, that they would have a plan or forceful language laid out on how this disgraceful situation is going to be rectified,” Staley said.

Although the FDA’s announcement does not mention it, the agency is requiring such a study.

Brainard said Gilead plans to start the study in at least 1,500 high-risk women in southern Africa — where the incidence of HIV in women is higher than in the United States — by the end of 2020. The FDA’s approval letter requires the company to complete the trial by December 2024.

Walensky said she is disappointed by the numbers and timeline of that trial.

“I want to see a large-scale, rapid effort to get data in women as soon as possible,” she said. “That, in my mind, is the only way to rectify this.”
AI Disclaimer: An advanced artificial intelligence (AI) system generated the content of this page on its own. This innovative technology conducts extensive research from a variety of reliable sources, performs rigorous fact-checking and verification, cleans up and balances biased or manipulated content, and presents a minimal factual summary that is just enough yet essential for you to function as an informed and educated citizen. Please keep in mind, however, that this system is an evolving technology, and as a result, the article may contain accidental inaccuracies or errors. We urge you to help us improve our site by reporting any inaccuracies you find using the "Contact Us" link at the bottom of this page. Your helpful feedback helps us improve our system and deliver more precise content. When you find an article of interest here, please look for the full and extensive coverage of this topic in traditional news sources, as they are written by professional journalists that we try to support, not replace. We appreciate your understanding and assistance.
Newsletter

Related Articles

0:00
0:00
Close
Altman Says GPT-5 Already Outpaces Him, Warns AI Could Automate 40% of Work
Russian Research Vessel 'Yantar' Tracked Mapping Europe’s Subsea Cables, Raising Security Alarms
Global Cruise Industry Posts Dramatic Comeback with 34.6 Million Passengers in 2024
U.S. Demands Brussels Scrutinize Digital Rules to Prevent Bias Against American Tech
Private Equity’s Fundraising Surge Triggers Concern of European Market Shake-Out
Tokyo’s Jimbōchō Named World’s Coolest Neighbourhood for 2025
European Officials Fear Trump May Shift Blame for Ukraine War onto EU
The Personality Rights Challenge in India’s AI Era
Italy Considers Freezing Retirement Age at 67 to Avert Scheduled Hike
Italian City to Impose Tax on Visiting Dogs Starting in 2026
Study Finds No Safe Level of Alcohol for Dementia Risk
Trump Says Ukraine Can Fully Restore Borders with NATO Backing
Europe Signals Stronger Support for Taiwan at Major Taipei Defence Show
Germany Weighs Excluding France from Key European Fighter Jet Programme
Cyberattack Disrupts Check-in and Boarding Systems at Major European Airports
Björn Borg Breaks Silence: Memoir Reveals Addiction, Shame and Cancer Battle
When Extremism Hijacks Idealism: How the Baader-Meinhof Gang Emerged and Fell
JWST Data Brings TRAPPIST-1e Closer to Earth-Like Habitability
Trump Orders $100,000 Fee on H-1B Visas and Launches ‘Gold Card’ Immigration Pathway
France’s Looming Budget Crisis and Political Fracture Raise Fears of Becoming Europe’s “Sick Man”
Three Russian MiG-31 Jets Breach Estonian Airspace in ‘Unprecedentedly Brazen’ NATO Incident
European manufacturers against ban on polluting cars: "The industry may collapse"
Turkish car manufacturer Togg Enters German Market with 5-Star Electric Sedan and SUV to Challenge European EV Brands
Christian Brueckner Released from German Prison after Serving Unrelated Sentence
World’s Longest Direct Flight China Eastern to Launch 29-Hour Shanghai–Buenos Aires Direct Flight via Auckland in December
New OpenAI Study Finds Majority of ChatGPT Use Is Personal, Not Professional
The conservative right spreads westward: a huge achievement for 'Alternative for Germany' in local elections
Pope Leo Warns of Societal Crisis Over Mega-CEO Pay, Citing Tesla’s Proposed Trillion-Dollar Package
Poland Green-Lights NATO Deployment in Response to Major Russian Drone Incursion
U.S. and China Agree on Framework to Shift TikTok to American Ownership
Le Pen Tightens the Pressure on Macron as France Edges Toward Political Breakdown
Czech Republic signs €1.34 billion contract for Leopard 2A8 main battle tanks with delivery from 2028
Penske Media Sues Google Over “AI Overviews,” Claiming It Uses Journalism Without Consent and Destroys Traffic
Indian Student Engineers Propose “Project REBIRTH” to Protect Aircraft from Crashes Using AI, Airbags and Smart Materials
One in Three Europeans Now Uses TikTok, According to the Chinese Tech Giant
Could AI Nursing Robots Help Healthcare Staffing Shortages?
NATO Deploys ‘Eastern Sentry’ After Russian Drones Violate Polish Airspace
The New Life of Novak Djokovic
German police raid AfD lawmaker’s offices in inquiry over Chinese payments
Volkswagen launches aggressive strategy to fend off Chinese challenge in Europe’s EV market
France Erupts in Mass ‘Block Everything’ Protests on New PM’s First Day
Poland Shoots Down Russian Drones in Airspace Violation During Ukraine Attack
Apple Introduces Ultra-Thin iPhone Air, Enhanced 17 Series and New Health-Focused Wearables
Macron Appoints Sébastien Lecornu as Prime Minister Amid Budget Crisis and Political Turmoil
Vatican hosts first Catholic LGBTQ pilgrimage
Apple Unveils iPhone 17 Series, iPhone Air, Apple Watch 11 and More at 'Awe Dropping' Event
France joins Eurozone’s ‘periphery’ as turmoil deepens, say investors
France Faces New Political Crisis, again, as Prime Minister Bayrou Pushed Out
Nayib Bukele Points Out Belgian Hypocrisy as Brussels Considers Sending Army into the Streets
France, at an Impasse, Heads Toward Another Government Collapse
×